Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03129542 · ClinicalTrials.gov registry record · Phase 1
Midodrine Hydrochloride in Early Sepsis
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03129542: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03129542 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03129542, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The investigators would like to determine if early administration of oral Midodrine in participants diagnosed with sepsis will impact blood pressures and decrease the need for and/or doses of intravenous pressor agents.
Interventions
- DRUG Placebo capsule
- DRUG Midodrine Hydrochloride 10 milligrams
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-08-30 |
| Est. Completion | 2020-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03129542
The ClinicalTrials.gov registry entry for NCT03129542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo capsule is the first listed.
NCT03129542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03129542 about?
NCT03129542 is a clinical study titled "Midodrine Hydrochloride in Early Sepsis". The investigators would like to determine if early administration of oral Midodrine in participants diagnosed with sepsis will impact blood pressures and decrease the need for and/or doses of intravenous pressor agents.
What is the current status of trial NCT03129542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-08-30. Estimated completion is 2020-05-15.
What interventions are being tested in trial NCT03129542?
The interventions under investigation include: Placebo capsule (DRUG), Midodrine Hydrochloride 10 milligrams (DRUG).
Who is sponsoring clinical trial NCT03129542?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.